Technical Analysis for VVUS - VIVUS, Inc.

Grade Last Price % Change Price Change
grade C 3.86 -1.03% -0.04
VVUS closed down 1.03 percent on Friday, May 24, 2019, on 22 percent of normal volume. It ran into resistance at its 50 day moving average.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical VVUS trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Fell Below 20 DMA Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Fell Below 50 DMA Bearish -1.03%
20 DMA Support Bullish -1.03%
Bollinger Band Squeeze Range Contraction -1.03%
Down 3 Days in a Row Weakness -1.03%
50 DMA Support Bullish -3.26%

Older signals for VVUS ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
VIVUS, Inc., a biopharmaceutical company, engages in developing and commercializing therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health. The company offers Qsymia, a drug for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol; and STENDRA for the treatment of erectile dysfunction. It also completed Phase II clinical studies of Qsymia for the treatment of obstructive sleep apnea; and Qsymia for the treatment of type 2 diabetes. The company has an agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. VIVUS, Inc. was founded in 1991 and is headquartered in Mountain View, California.
Medicine Chemistry Health Biopharmaceutical Diabetes Obesity Diabetes Mellitus Hypertension Psychiatric Diagnosis Obstructive Sleep Apnea Sleep Disorders Sleep Apnea Erectile Dysfunction Treatment Of Obesity Chronic Weight Management Female Sexual Dysfunction High Cholesterol
Is VVUS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 9.1
52 Week Low 2.15
Average Volume 54,239
200-Day Moving Average 4.2205
50-Day Moving Average 3.904
20-Day Moving Average 3.885
10-Day Moving Average 3.921
Average True Range 0.1857
ADX 13.13
+DI 14.0393
-DI 15.5599
Chandelier Exit (Long, 3 ATRs ) 3.5359
Chandelier Exit (Short, 3 ATRs ) 4.0571
Upper Bollinger Band 4.1339
Lower Bollinger Band 3.6361
Percent B (%b) 0.45
BandWidth 12.813385
MACD Line 0.0218
MACD Signal Line 0.0117
MACD Histogram 0.01
Fundamentals Value
Market Cap 408.45 Million
Num Shares 106 Million
EPS 0.31
Price-to-Earnings (P/E) Ratio 12.45
Price-to-Sales 0.55
Price-to-Book 13.45
PEG Ratio -2.24
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.10
Resistance 3 (R3) 4.12 4.06 4.06
Resistance 2 (R2) 4.06 4.00 4.05 4.05
Resistance 1 (R1) 3.96 3.96 4.01 3.94 4.04
Pivot Point 3.89 3.89 3.92 3.89 3.89
Support 1 (S1) 3.80 3.83 3.85 3.78 3.68
Support 2 (S2) 3.73 3.79 3.72 3.67
Support 3 (S3) 3.63 3.73 3.66
Support 4 (S4) 3.62